吡格列酮对非糖尿病代谢综合征患者的干预治疗

Intervention Study on Effect of Pioglitazone on Patients with Non-diabetic Metabolic Syndrome

目的：观察吡格列酮对非糖尿病代谢综合征干预治疗的疗效。方法；选择非糖尿病代谢综合征患者84例，随机分为两组，A组（对照组）42例，予常规治疗；B组（干预组）42例，在常规治疗基础上加用吡格列酮15mg，每日1次口服，连服24周。监测治疗前、后空腹血糖（FPG）及餐后2h血糖（2HPG）、空腹胰岛素（FINS）、糖化血红蛋白（HbAlc）、血脂、血压（BP）、胰岛素抵抗指数（HOMA-IR）、血清高敏C-反应蛋白（hsC-RP）等。结果：治疗24周后两组FPO、2HPO、FINS、HbAc、BP、TG、hsC-RP及HOMA-IR均下降，HDL-C升高，B组下降明显，两组之间比较差异有统计学意义（P〈0．05-P〈0．01）。结论：对非糖尿病代谢综合征患者，吡格列酮可显著改善糖脂代谢，减轻氓和炎症状态，减少心血管疾病发生。

Objective： To evaluate the intervention effect of pioglitazone on patients with non-diabetic metabolic syndrome（MS）. Methods. 84 non-diabetic MS patients were divided randomly into group A（n=42） ：conventional treatment only,and group B（n=42） ： pioglitazone 15mg po qd plus conventional treatment and continuous 24 weeks. Fasting plasma glucose（FPG）, postprandial glucose following meal 2 hours later（2HPG）, fasting insulin（FINS）, glycosylated hemoglobin（HbAlc ）, plasma lipid, HOMA-IR, SBP, DBP and hsC-RP were detected before and after medication separately. Results：After treatment, FPG. 2HPG, FINS. HbAlc. BP. TG. hsC-RP and HOMA-IR counts were decreased and HDL-C increased significantly in both groups. Which were changed more in group B than those in group A（P〈0. 05- P〈0.01）. Conclusion： In non-diabetic MS patients, pioglitazone can improve plasma glucose and lipids, less on insulin resistance and inflammatory state,reduction of the incidence of cardiovascular disease.